ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Business

Fujifilm adds new approach to regenerative treatment

TOKYO -- Fujifilm Holdings is expanding into a different branch of regenerative medicine using  stem cells found in bone marrow and fatty tissue .

     Mesenchymale stem cells are considered ideal for treating bone and muscle conditions. Those treatments are expected to be developed in addition to those that make use of somatic cells and induced pluripotent (iPS) stem cells.

     Clinical research is set to begin sometime this year. Mesenchymal stem cells taken from patients will be grown and used to treat damaged cartilage and meniscuses, among other maladies.

     Fujifilm is also aiming to eventually develop treatment that will utilize cells from healthy donors, and not just from patients themselves. That way, there will be a supply of ready-made tissue at hand, instead of waiting weeks or months growing new tissue.

     For treatments using iPS cells, clinical trials targeting patients suffering from eye problems, heart ailments and neurological disorders are set to begin by 2019. They will be done through a U.S. startup that was made into a subsidiary last spring.

     The global regenerative medicine market will grow to 38 trillion yen ($336 billion) by 2050, estimates by Japan's Ministry of Economy, Trade and Industry show. Fujifilm aims to become an integrated manufacturer in the field.

(Nikkei)

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media